Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 7(63), 2019

DOI: 10.1128/aac.00425-19

Links

Tools

Export citation

Search in Google Scholar

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

Journal article published in 2019 by Yuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, Alexandre P. Zavascki, Hsinyin Tsai, Xun Tao, Dhruvitkumar S. Sutaria, Arnold Louie, John D. Boyce ORCID, Deanna Deveson Lucas, Tae Hwan Kim, Brian T. Tsuji, Robert A. Bonomo, George L. Drusano, Jürgen B. Bulitta ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

There is a great need for efficacious therapies against Gram-negative bacteria. Double β-lactam combination(s) (DBL) are relatively safe, and preclinical data are promising; however, their clinical role has not been well defined.